Luo, Guanglin; Chen, Ling; Burton, Catherine R.; Xiao, Hong; Sivaprakasam, Prasanna; Krause, Carol M.; Cao, Yang; Liu, Nengyin; Lippy, Jonathan; Clarke, Wendy J.; Snow, Kimberly; Raybon, Joseph; Arora, Vinod; Pokross, Matt; Kish, Kevin; Lewis, Hal A.; Langley, David R.; Macor, John E.; Dubowchik, Gene M. published the artcile< Discovery of Isonicotinamides as Highly Selective, Brain Penetrable, and Orally Active Glycogen Synthase Kinase-3 Inhibitors>, Synthetic Route of 112-63-0, the main research area is preparation isonicotinamide brain glycogen synthase kinase inhibitor antitumor neoplasm; crystal structure.
GSK-3 is a serine/threonine kinase that has numerous substrates. Many of these proteins are involved in the regulation of diverse cellular functions, including metabolism, differentiation, proliferation, and apoptosis. Inhibition of GSK-3 may be useful in treating a number of diseases including Alzheimer’s disease (AD), type II diabetes, mood disorders, and some cancers, but the approach poses significant challenges. Here, the authors present a class of isonicotinamides, e.g. I [R = F, Cl] that are potent, highly kinase-selective GSK-3 inhibitors, the members of which demonstrated oral activity in a triple-transgenic mouse model of AD. The remarkably high kinase selectivity and straightforward synthesis of these compounds bode well for their further exploration as tool compounds and therapeutics.
Journal of Medicinal Chemistry published new progress about Antitumor agents. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Synthetic Route of 112-63-0.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics